Is a Meltdown on the Way for Moderna Stock?_老虎社区_美港股上老虎

Is a Meltdown on the Way for Moderna Stock?

Motley Fool2021-07-30

Move over, Murphy's law. Everything that could go right for Moderna (NASDAQ:MRNA) seems to be going right. The company was added to the S&P 500 index. Sales of its COVID-19 vaccine are booming, and ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

MYMYMY
·2021-07-30
Wow
回复
点赞
举报
ngsebas
·2021-07-30
Oh no. I see
回复
点赞
举报
Dtyl
·2021-07-30
Moderna is not keeping up
回复
点赞
举报
收起
- Tothestars:
  Pfier ftw
  2021-07-30
  回复
  举报
carceng
·2021-07-30
Hi please like and comment thank you
回复
1
举报
收起
- Benedict_cyh:
  N
  2021-07-30
  回复
  举报
Wolverine
·2021-07-30
Yes please
回复
点赞
举报
kjsin
·2021-07-30
Murphy law!
回复
点赞
举报
OoPiPi
·2021-07-30
Comment and like please
回复
2
举报
收起
- 7cs:
  okay
  2021-07-30
  回复
  举报
OoPiPi
·2021-07-30
High tech vaccine utilising mRNA technology !
回复
2
举报
boonk
·2021-07-30
Yes please. Fall to 150
回复
6
举报
Staricelock
·2021-07-30
Hmmm
回复
3
举报
JeebeeTan
·2021-07-30
👍🏻
回复
2
举报
收起
- CTigger:
  yep
  2021-07-30
  回复
  举报
- Siewleerocks:
  Yes
  2021-07-30
  回复
  举报
soybeans
·2021-07-30
Chance to grab some Moderna if it ever happens.
回复
2
举报
收起
- Coo24:
  Ok
  2021-07-30
  回复
  举报
- Matt_cjx:
  Ha
  2021-07-30
  回复
  举报
- AhSon:
  Is it
  2021-07-30
  回复
  举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2155373781?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-07-30 20:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2155373781","market":"us","top_or_hot":-1,"title":"Is a Meltdown on the Way for Moderna Stock?","media":"Motley Fool","content":"<div>\n<p>Move over, Murphy's law. Everything that could go right for Moderna (NASDAQ:MRNA) seems to be going right. The company was added to the S&P 500 index. Sales of its COVID-19 vaccine are booming, and ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/30/is-a-meltdown-on-the-way-for-moderna-stock/\">网页链接</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is a Meltdown on the Way for Moderna Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs a Meltdown on the Way for Moderna Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 20:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/30/is-a-meltdown-on-the-way-for-moderna-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Move over, Murphy's law. Everything that could go right for Moderna (NASDAQ:MRNA) seems to be going right. The company was added to the S&P 500 index. Sales of its COVID-19 vaccine are booming, and ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/30/is-a-meltdown-on-the-way-for-moderna-stock/\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://www.fool.com/investing/2021/07/30/is-a-meltdown-on-the-way-for-moderna-stock/","article_id":"2155373781","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2155373781","pubTimestamp":1627647922,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"There are certainly reasons to think the biotech stock is overpriced right now.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"现代股票即将崩溃吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":0.9},"content_text":"Move over, Murphy's law. Everything that could go right for Moderna (NASDAQ:MRNA) seems to be going right. The company was added to the S&P 500 index. Sales of its COVID-19 vaccine are booming, and its share price has more than tripled so far this year.\nHowever, all of this success could have some investors wondering just how long the momentum will last. And sometimes, when a good run ends, it isn't a pretty picture. Could a meltdown be on the way for Moderna stock?\nImage source: Getty Images.\nLofty heights\nThere's no question that Moderna's valuation has reached lofty heights of late. The vaccine-maker's market cap is close to $130 billion, making Moderna one of the biggest biotech stocks on the market.\nLet's put that market cap in perspective. Moderna has one product on the market, compared to a multitude of products for Pfizer. Moderna's projected sales this year are only a fraction of what Pfizer will likely make. The company's pipeline looks tiny versus Pfizer's, and yet Moderna is now valued at more than half of Pfizer's market cap.\nConsider Regeneron and Vertex, two of the most successful biotechs around. Regeneron has multiple blockbuster drugs on the market, and Vertex enjoys a monopoly in treating the underlying cause of cystic fibrosis. Moderna is currently worth more than Regeneron and Vertex combined.\nConsiderable uncertainty\nModerna's valuation probably wouldn't be very concerning if the company could count on the revenue that it will make in 2021 and 2022 continuing over the long run. However, there's considerable uncertainty as to whether or not that will be the case.\nNo one knows for sure how long Moderna's COVID-19 vaccine will provide protection against infection. The longer the duration of immunity, the fewer vaccine doses that the company will sell.\nPerhaps emerging coronavirus variants could force the need for booster doses. For now, though, Moderna's vaccine appears to be holding up relatively well against variants, especially in preventing severe cases of COVID-19.\nRemember, too, that Moderna's vaccine currently requires two doses. Even if booster shots are needed going forward, it's probable that only single shots will be used.\nThis lower volume will negatively impact Moderna's future revenue unless the company doubles its price per dose. If Moderna took that option, though, it could set the stage for rivals to capture more market share.\nA meltdown in the making?\nA sky-high valuation plus serious questions about the future could add up to a meltdown in the making for many stocks. Will that happen with Moderna? Maybe.\nI've been bullish about Moderna for a long time. However, even I don't think it's worth more than half the market cap of Pfizer and more than Regeneron and Vertex combined.\nStill, though, I don't predict a meltdown for Moderna stock. Yes, I fully expect the biotech's shares will fall from current levels. However, my take is that there'll be more of a gradual decline instead of a crash.\nThere's a real possibility that the current worries about the delta variant fade away. As those concerns decrease, so could Moderna's share price. But that's more likely to happen over a period of months instead of on a super-quick basis.\nEven if Moderna stock falls, as I think it eventually will, my view of the company's long-term prospects remains upbeat. I look for Moderna to crank out more successful messenger RNA (mRNA) vaccines and therapies over the next decade and beyond.\nThe company won't be able to avoid Murphy's law forever. However, I anticipate that more will go right for Moderna over the long run than will go wrong.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":806296170,"gmtCreate":1627656372690,"gmtModify":1633757352582,"author":{"id":"4090287568866580","authorId":"4090287568866580","name":"MYMYMY","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4090287568866580","authorIdStr":"4090287568866580"},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/806296170","repostId":2155373781,"repostType":4,"repost":{"id":"2155373781","pubTimestamp":1627647922,"share":"https://www.laohu8.com/m/news/2155373781?lang=&edition=full","pubTime":"2021-07-30 20:25","market":"us","language":"en","title":"Is a Meltdown on the Way for Moderna Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2155373781","media":"Motley Fool","summary":"There are certainly reasons to think the biotech stock is overpriced right now.","content":"<p>Move over, Murphy's law. Everything that could go right for&nbsp;<b>Moderna</b> (NASDAQ:MRNA) seems to be going right. The company was added to the <b>S&amp;P 500</b> index. Sales of its COVID-19 vaccine are booming, and its share price has more than tripled so far this year.</p>\n<p>However, all of this success could have some investors wondering just how long the momentum will last. And sometimes, when a good run ends, it isn't a pretty picture. Could a meltdown be on the way for Moderna stock?</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f6c071faeb9786d52d87adcab160eab7\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Lofty heights</h2>\n<p>There's no question that Moderna's valuation has reached lofty heights of late. The vaccine-maker's market cap is close to $130 billion, making Moderna <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the biggest biotech stocks on the market.</p>\n<p>Let's put that market cap in perspective. Moderna has one product on the market, compared to a multitude of products for <b>Pfizer</b>. Moderna's projected sales this year are only a fraction of what Pfizer will likely make. The company's pipeline looks tiny versus Pfizer's, and yet Moderna is now valued at more than half of Pfizer's market cap.</p>\n<p>Consider <b>Regeneron</b>&nbsp;and <b>Vertex</b>, two of the most successful biotechs around. Regeneron has multiple blockbuster drugs on the market, and Vertex enjoys a monopoly in treating the underlying cause of cystic fibrosis. Moderna is currently worth more than Regeneron and Vertex <i>combined</i>.</p>\n<h2>Considerable uncertainty</h2>\n<p>Moderna's valuation probably wouldn't be very concerning if the company could count on the revenue that it will make in 2021 and 2022 continuing over the long run. However, there's considerable uncertainty as to whether or not that will be the case.</p>\n<p>No one knows for sure how long Moderna's COVID-19 vaccine will provide protection against infection. The longer the duration of immunity, the fewer vaccine doses that the company will sell.</p>\n<p>Perhaps emerging coronavirus variants could force the need for booster doses. For now, though, Moderna's vaccine appears to be holding up relatively well against variants, especially in preventing severe cases of COVID-19.</p>\n<p>Remember, too, that Moderna's vaccine currently requires two doses. Even if booster shots are needed going forward, it's probable that only single shots will be used.</p>\n<p>This lower volume will negatively impact Moderna's future revenue unless the company doubles its price per dose. If Moderna took that option, though, it could set the stage for rivals to capture more market share.</p>\n<h2>A meltdown in the making?</h2>\n<p>A sky-high valuation plus serious questions about the future could add up to a meltdown in the making for many stocks. Will that happen with Moderna? Maybe.</p>\n<p>I've been bullish about Moderna for a long time. However, even I don't think it's worth more than half the market cap of Pfizer and more than Regeneron and Vertex combined.</p>\n<p>Still, though, I don't predict a meltdown for Moderna stock. Yes, I fully expect the biotech's shares will fall from current levels. However, my take is that there'll be more of a gradual decline instead of a crash.</p>\n<p>There's a real possibility that the current worries about the delta variant fade away. As those concerns decrease, so could Moderna's share price. But that's more likely to happen over a period of months instead of on a super-quick basis.</p>\n<p>Even if Moderna stock falls, as I think it eventually will, my view of the company's long-term prospects remains upbeat. I look for Moderna to crank out more successful messenger RNA (mRNA) vaccines and therapies over the next decade and beyond.</p>\n<p>The company won't be able to avoid Murphy's law forever. However, I anticipate that more will go right for Moderna over the long run than will go wrong.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is a Meltdown on the Way for Moderna Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs a Meltdown on the Way for Moderna Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 20:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/30/is-a-meltdown-on-the-way-for-moderna-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Move over, Murphy's law. Everything that could go right for Moderna (NASDAQ:MRNA) seems to be going right. The company was added to the S&P 500 index. Sales of its COVID-19 vaccine are booming, and ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/30/is-a-meltdown-on-the-way-for-moderna-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/07/30/is-a-meltdown-on-the-way-for-moderna-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155373781","content_text":"Move over, Murphy's law. Everything that could go right for Moderna (NASDAQ:MRNA) seems to be going right. The company was added to the S&P 500 index. Sales of its COVID-19 vaccine are booming, and its share price has more than tripled so far this year.\nHowever, all of this success could have some investors wondering just how long the momentum will last. And sometimes, when a good run ends, it isn't a pretty picture. Could a meltdown be on the way for Moderna stock?\nImage source: Getty Images.\nLofty heights\nThere's no question that Moderna's valuation has reached lofty heights of late. The vaccine-maker's market cap is close to $130 billion, making Moderna one of the biggest biotech stocks on the market.\nLet's put that market cap in perspective. Moderna has one product on the market, compared to a multitude of products for Pfizer. Moderna's projected sales this year are only a fraction of what Pfizer will likely make. The company's pipeline looks tiny versus Pfizer's, and yet Moderna is now valued at more than half of Pfizer's market cap.\nConsider Regeneron and Vertex, two of the most successful biotechs around. Regeneron has multiple blockbuster drugs on the market, and Vertex enjoys a monopoly in treating the underlying cause of cystic fibrosis. Moderna is currently worth more than Regeneron and Vertex combined.\nConsiderable uncertainty\nModerna's valuation probably wouldn't be very concerning if the company could count on the revenue that it will make in 2021 and 2022 continuing over the long run. However, there's considerable uncertainty as to whether or not that will be the case.\nNo one knows for sure how long Moderna's COVID-19 vaccine will provide protection against infection. The longer the duration of immunity, the fewer vaccine doses that the company will sell.\nPerhaps emerging coronavirus variants could force the need for booster doses. For now, though, Moderna's vaccine appears to be holding up relatively well against variants, especially in preventing severe cases of COVID-19.\nRemember, too, that Moderna's vaccine currently requires two doses. Even if booster shots are needed going forward, it's probable that only single shots will be used.\nThis lower volume will negatively impact Moderna's future revenue unless the company doubles its price per dose. If Moderna took that option, though, it could set the stage for rivals to capture more market share.\nA meltdown in the making?\nA sky-high valuation plus serious questions about the future could add up to a meltdown in the making for many stocks. Will that happen with Moderna? Maybe.\nI've been bullish about Moderna for a long time. However, even I don't think it's worth more than half the market cap of Pfizer and more than Regeneron and Vertex combined.\nStill, though, I don't predict a meltdown for Moderna stock. Yes, I fully expect the biotech's shares will fall from current levels. However, my take is that there'll be more of a gradual decline instead of a crash.\nThere's a real possibility that the current worries about the delta variant fade away. As those concerns decrease, so could Moderna's share price. But that's more likely to happen over a period of months instead of on a super-quick basis.\nEven if Moderna stock falls, as I think it eventually will, my view of the company's long-term prospects remains upbeat. I look for Moderna to crank out more successful messenger RNA (mRNA) vaccines and therapies over the next decade and beyond.\nThe company won't be able to avoid Murphy's law forever. However, I anticipate that more will go right for Moderna over the long run than will go wrong.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":806873944,"gmtCreate":1627651715088,"gmtModify":1633757433025,"author":{"id":"4087265924884810","authorId":"4087265924884810","name":"ngsebas","avatar":"https://static.tigerbbs.com/41b05688e3d2d10fea876cc9c60f62ab","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4087265924884810","authorIdStr":"4087265924884810"},"htmlText":"Oh no. I see","listText":"Oh no. I see","text":"Oh no. I see","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/806873944","repostId":2155373781,"repostType":4,"repost":{"id":"2155373781","pubTimestamp":1627647922,"share":"https://www.laohu8.com/m/news/2155373781?lang=&edition=full","pubTime":"2021-07-30 20:25","market":"us","language":"en","title":"Is a Meltdown on the Way for Moderna Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2155373781","media":"Motley Fool","summary":"There are certainly reasons to think the biotech stock is overpriced right now.","content":"<p>Move over, Murphy's law. Everything that could go right for&nbsp;<b>Moderna</b> (NASDAQ:MRNA) seems to be going right. The company was added to the <b>S&amp;P 500</b> index. Sales of its COVID-19 vaccine are booming, and its share price has more than tripled so far this year.</p>\n<p>However, all of this success could have some investors wondering just how long the momentum will last. And sometimes, when a good run ends, it isn't a pretty picture. Could a meltdown be on the way for Moderna stock?</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f6c071faeb9786d52d87adcab160eab7\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Lofty heights</h2>\n<p>There's no question that Moderna's valuation has reached lofty heights of late. The vaccine-maker's market cap is close to $130 billion, making Moderna <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the biggest biotech stocks on the market.</p>\n<p>Let's put that market cap in perspective. Moderna has one product on the market, compared to a multitude of products for <b>Pfizer</b>. Moderna's projected sales this year are only a fraction of what Pfizer will likely make. The company's pipeline looks tiny versus Pfizer's, and yet Moderna is now valued at more than half of Pfizer's market cap.</p>\n<p>Consider <b>Regeneron</b>&nbsp;and <b>Vertex</b>, two of the most successful biotechs around. Regeneron has multiple blockbuster drugs on the market, and Vertex enjoys a monopoly in treating the underlying cause of cystic fibrosis. Moderna is currently worth more than Regeneron and Vertex <i>combined</i>.</p>\n<h2>Considerable uncertainty</h2>\n<p>Moderna's valuation probably wouldn't be very concerning if the company could count on the revenue that it will make in 2021 and 2022 continuing over the long run. However, there's considerable uncertainty as to whether or not that will be the case.</p>\n<p>No one knows for sure how long Moderna's COVID-19 vaccine will provide protection against infection. The longer the duration of immunity, the fewer vaccine doses that the company will sell.</p>\n<p>Perhaps emerging coronavirus variants could force the need for booster doses. For now, though, Moderna's vaccine appears to be holding up relatively well against variants, especially in preventing severe cases of COVID-19.</p>\n<p>Remember, too, that Moderna's vaccine currently requires two doses. Even if booster shots are needed going forward, it's probable that only single shots will be used.</p>\n<p>This lower volume will negatively impact Moderna's future revenue unless the company doubles its price per dose. If Moderna took that option, though, it could set the stage for rivals to capture more market share.</p>\n<h2>A meltdown in the making?</h2>\n<p>A sky-high valuation plus serious questions about the future could add up to a meltdown in the making for many stocks. Will that happen with Moderna? Maybe.</p>\n<p>I've been bullish about Moderna for a long time. However, even I don't think it's worth more than half the market cap of Pfizer and more than Regeneron and Vertex combined.</p>\n<p>Still, though, I don't predict a meltdown for Moderna stock. Yes, I fully expect the biotech's shares will fall from current levels. However, my take is that there'll be more of a gradual decline instead of a crash.</p>\n<p>There's a real possibility that the current worries about the delta variant fade away. As those concerns decrease, so could Moderna's share price. But that's more likely to happen over a period of months instead of on a super-quick basis.</p>\n<p>Even if Moderna stock falls, as I think it eventually will, my view of the company's long-term prospects remains upbeat. I look for Moderna to crank out more successful messenger RNA (mRNA) vaccines and therapies over the next decade and beyond.</p>\n<p>The company won't be able to avoid Murphy's law forever. However, I anticipate that more will go right for Moderna over the long run than will go wrong.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is a Meltdown on the Way for Moderna Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs a Meltdown on the Way for Moderna Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 20:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/30/is-a-meltdown-on-the-way-for-moderna-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Move over, Murphy's law. Everything that could go right for Moderna (NASDAQ:MRNA) seems to be going right. The company was added to the S&P 500 index. Sales of its COVID-19 vaccine are booming, and ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/30/is-a-meltdown-on-the-way-for-moderna-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/07/30/is-a-meltdown-on-the-way-for-moderna-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155373781","content_text":"Move over, Murphy's law. Everything that could go right for Moderna (NASDAQ:MRNA) seems to be going right. The company was added to the S&P 500 index. Sales of its COVID-19 vaccine are booming, and its share price has more than tripled so far this year.\nHowever, all of this success could have some investors wondering just how long the momentum will last. And sometimes, when a good run ends, it isn't a pretty picture. Could a meltdown be on the way for Moderna stock?\nImage source: Getty Images.\nLofty heights\nThere's no question that Moderna's valuation has reached lofty heights of late. The vaccine-maker's market cap is close to $130 billion, making Moderna one of the biggest biotech stocks on the market.\nLet's put that market cap in perspective. Moderna has one product on the market, compared to a multitude of products for Pfizer. Moderna's projected sales this year are only a fraction of what Pfizer will likely make. The company's pipeline looks tiny versus Pfizer's, and yet Moderna is now valued at more than half of Pfizer's market cap.\nConsider Regeneron and Vertex, two of the most successful biotechs around. Regeneron has multiple blockbuster drugs on the market, and Vertex enjoys a monopoly in treating the underlying cause of cystic fibrosis. Moderna is currently worth more than Regeneron and Vertex combined.\nConsiderable uncertainty\nModerna's valuation probably wouldn't be very concerning if the company could count on the revenue that it will make in 2021 and 2022 continuing over the long run. However, there's considerable uncertainty as to whether or not that will be the case.\nNo one knows for sure how long Moderna's COVID-19 vaccine will provide protection against infection. The longer the duration of immunity, the fewer vaccine doses that the company will sell.\nPerhaps emerging coronavirus variants could force the need for booster doses. For now, though, Moderna's vaccine appears to be holding up relatively well against variants, especially in preventing severe cases of COVID-19.\nRemember, too, that Moderna's vaccine currently requires two doses. Even if booster shots are needed going forward, it's probable that only single shots will be used.\nThis lower volume will negatively impact Moderna's future revenue unless the company doubles its price per dose. If Moderna took that option, though, it could set the stage for rivals to capture more market share.\nA meltdown in the making?\nA sky-high valuation plus serious questions about the future could add up to a meltdown in the making for many stocks. Will that happen with Moderna? Maybe.\nI've been bullish about Moderna for a long time. However, even I don't think it's worth more than half the market cap of Pfizer and more than Regeneron and Vertex combined.\nStill, though, I don't predict a meltdown for Moderna stock. Yes, I fully expect the biotech's shares will fall from current levels. However, my take is that there'll be more of a gradual decline instead of a crash.\nThere's a real possibility that the current worries about the delta variant fade away. As those concerns decrease, so could Moderna's share price. But that's more likely to happen over a period of months instead of on a super-quick basis.\nEven if Moderna stock falls, as I think it eventually will, my view of the company's long-term prospects remains upbeat. I look for Moderna to crank out more successful messenger RNA (mRNA) vaccines and therapies over the next decade and beyond.\nThe company won't be able to avoid Murphy's law forever. However, I anticipate that more will go right for Moderna over the long run than will go wrong.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":806843512,"gmtCreate":1627651340436,"gmtModify":1633757439068,"author":{"id":"3579638888013190","authorId":"3579638888013190","name":"Dtyl","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3579638888013190","authorIdStr":"3579638888013190"},"htmlText":"Moderna is not keeping up&nbsp;","listText":"Moderna is not keeping up&nbsp;","text":"Moderna is not keeping up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/806843512","repostId":2155373781,"repostType":4,"repost":{"id":"2155373781","pubTimestamp":1627647922,"share":"https://www.laohu8.com/m/news/2155373781?lang=&edition=full","pubTime":"2021-07-30 20:25","market":"us","language":"en","title":"Is a Meltdown on the Way for Moderna Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2155373781","media":"Motley Fool","summary":"There are certainly reasons to think the biotech stock is overpriced right now.","content":"<p>Move over, Murphy's law. Everything that could go right for&nbsp;<b>Moderna</b> (NASDAQ:MRNA) seems to be going right. The company was added to the <b>S&amp;P 500</b> index. Sales of its COVID-19 vaccine are booming, and its share price has more than tripled so far this year.</p>\n<p>However, all of this success could have some investors wondering just how long the momentum will last. And sometimes, when a good run ends, it isn't a pretty picture. Could a meltdown be on the way for Moderna stock?</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f6c071faeb9786d52d87adcab160eab7\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Lofty heights</h2>\n<p>There's no question that Moderna's valuation has reached lofty heights of late. The vaccine-maker's market cap is close to $130 billion, making Moderna <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the biggest biotech stocks on the market.</p>\n<p>Let's put that market cap in perspective. Moderna has one product on the market, compared to a multitude of products for <b>Pfizer</b>. Moderna's projected sales this year are only a fraction of what Pfizer will likely make. The company's pipeline looks tiny versus Pfizer's, and yet Moderna is now valued at more than half of Pfizer's market cap.</p>\n<p>Consider <b>Regeneron</b>&nbsp;and <b>Vertex</b>, two of the most successful biotechs around. Regeneron has multiple blockbuster drugs on the market, and Vertex enjoys a monopoly in treating the underlying cause of cystic fibrosis. Moderna is currently worth more than Regeneron and Vertex <i>combined</i>.</p>\n<h2>Considerable uncertainty</h2>\n<p>Moderna's valuation probably wouldn't be very concerning if the company could count on the revenue that it will make in 2021 and 2022 continuing over the long run. However, there's considerable uncertainty as to whether or not that will be the case.</p>\n<p>No one knows for sure how long Moderna's COVID-19 vaccine will provide protection against infection. The longer the duration of immunity, the fewer vaccine doses that the company will sell.</p>\n<p>Perhaps emerging coronavirus variants could force the need for booster doses. For now, though, Moderna's vaccine appears to be holding up relatively well against variants, especially in preventing severe cases of COVID-19.</p>\n<p>Remember, too, that Moderna's vaccine currently requires two doses. Even if booster shots are needed going forward, it's probable that only single shots will be used.</p>\n<p>This lower volume will negatively impact Moderna's future revenue unless the company doubles its price per dose. If Moderna took that option, though, it could set the stage for rivals to capture more market share.</p>\n<h2>A meltdown in the making?</h2>\n<p>A sky-high valuation plus serious questions about the future could add up to a meltdown in the making for many stocks. Will that happen with Moderna? Maybe.</p>\n<p>I've been bullish about Moderna for a long time. However, even I don't think it's worth more than half the market cap of Pfizer and more than Regeneron and Vertex combined.</p>\n<p>Still, though, I don't predict a meltdown for Moderna stock. Yes, I fully expect the biotech's shares will fall from current levels. However, my take is that there'll be more of a gradual decline instead of a crash.</p>\n<p>There's a real possibility that the current worries about the delta variant fade away. As those concerns decrease, so could Moderna's share price. But that's more likely to happen over a period of months instead of on a super-quick basis.</p>\n<p>Even if Moderna stock falls, as I think it eventually will, my view of the company's long-term prospects remains upbeat. I look for Moderna to crank out more successful messenger RNA (mRNA) vaccines and therapies over the next decade and beyond.</p>\n<p>The company won't be able to avoid Murphy's law forever. However, I anticipate that more will go right for Moderna over the long run than will go wrong.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is a Meltdown on the Way for Moderna Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs a Meltdown on the Way for Moderna Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 20:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/30/is-a-meltdown-on-the-way-for-moderna-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Move over, Murphy's law. Everything that could go right for Moderna (NASDAQ:MRNA) seems to be going right. The company was added to the S&P 500 index. Sales of its COVID-19 vaccine are booming, and ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/30/is-a-meltdown-on-the-way-for-moderna-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/07/30/is-a-meltdown-on-the-way-for-moderna-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155373781","content_text":"Move over, Murphy's law. Everything that could go right for Moderna (NASDAQ:MRNA) seems to be going right. The company was added to the S&P 500 index. Sales of its COVID-19 vaccine are booming, and its share price has more than tripled so far this year.\nHowever, all of this success could have some investors wondering just how long the momentum will last. And sometimes, when a good run ends, it isn't a pretty picture. Could a meltdown be on the way for Moderna stock?\nImage source: Getty Images.\nLofty heights\nThere's no question that Moderna's valuation has reached lofty heights of late. The vaccine-maker's market cap is close to $130 billion, making Moderna one of the biggest biotech stocks on the market.\nLet's put that market cap in perspective. Moderna has one product on the market, compared to a multitude of products for Pfizer. Moderna's projected sales this year are only a fraction of what Pfizer will likely make. The company's pipeline looks tiny versus Pfizer's, and yet Moderna is now valued at more than half of Pfizer's market cap.\nConsider Regeneron and Vertex, two of the most successful biotechs around. Regeneron has multiple blockbuster drugs on the market, and Vertex enjoys a monopoly in treating the underlying cause of cystic fibrosis. Moderna is currently worth more than Regeneron and Vertex combined.\nConsiderable uncertainty\nModerna's valuation probably wouldn't be very concerning if the company could count on the revenue that it will make in 2021 and 2022 continuing over the long run. However, there's considerable uncertainty as to whether or not that will be the case.\nNo one knows for sure how long Moderna's COVID-19 vaccine will provide protection against infection. The longer the duration of immunity, the fewer vaccine doses that the company will sell.\nPerhaps emerging coronavirus variants could force the need for booster doses. For now, though, Moderna's vaccine appears to be holding up relatively well against variants, especially in preventing severe cases of COVID-19.\nRemember, too, that Moderna's vaccine currently requires two doses. Even if booster shots are needed going forward, it's probable that only single shots will be used.\nThis lower volume will negatively impact Moderna's future revenue unless the company doubles its price per dose. If Moderna took that option, though, it could set the stage for rivals to capture more market share.\nA meltdown in the making?\nA sky-high valuation plus serious questions about the future could add up to a meltdown in the making for many stocks. Will that happen with Moderna? Maybe.\nI've been bullish about Moderna for a long time. However, even I don't think it's worth more than half the market cap of Pfizer and more than Regeneron and Vertex combined.\nStill, though, I don't predict a meltdown for Moderna stock. Yes, I fully expect the biotech's shares will fall from current levels. However, my take is that there'll be more of a gradual decline instead of a crash.\nThere's a real possibility that the current worries about the delta variant fade away. As those concerns decrease, so could Moderna's share price. But that's more likely to happen over a period of months instead of on a super-quick basis.\nEven if Moderna stock falls, as I think it eventually will, my view of the company's long-term prospects remains upbeat. I look for Moderna to crank out more successful messenger RNA (mRNA) vaccines and therapies over the next decade and beyond.\nThe company won't be able to avoid Murphy's law forever. However, I anticipate that more will go right for Moderna over the long run than will go wrong.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5380303,"gmtCreate":1627652015716,"gmtModify":1635164064872,"authorId":3582064176289101,"author":{"id":3582064176289101,"idStr":"3582064176289101","authorId":3582064176289101,"name":"Tothestars","avatar":"https://static.tigerbbs.com/cd834243c50034fe5fa673b215e1bdb3","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":806843512,"type":1,"supId":0,"prevId":0,"content":"Pfier ftw","text":"Pfier ftw","html":"Pfier ftw"}],"langContent":"EN"},{"id":806856828,"gmtCreate":1627650943464,"gmtModify":1633757444740,"author":{"id":"3566353609041424","authorId":"3566353609041424","name":"carceng","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3566353609041424","authorIdStr":"3566353609041424"},"htmlText":"Hi please like and comment thank you","listText":"Hi please like and comment thank you","text":"Hi please like and comment thank you","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/806856828","repostId":2155373781,"repostType":4,"repost":{"id":"2155373781","pubTimestamp":1627647922,"share":"https://www.laohu8.com/m/news/2155373781?lang=&edition=full","pubTime":"2021-07-30 20:25","market":"us","language":"en","title":"Is a Meltdown on the Way for Moderna Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2155373781","media":"Motley Fool","summary":"There are certainly reasons to think the biotech stock is overpriced right now.","content":"<p>Move over, Murphy's law. Everything that could go right for&nbsp;<b>Moderna</b> (NASDAQ:MRNA) seems to be going right. The company was added to the <b>S&amp;P 500</b> index. Sales of its COVID-19 vaccine are booming, and its share price has more than tripled so far this year.</p>\n<p>However, all of this success could have some investors wondering just how long the momentum will last. And sometimes, when a good run ends, it isn't a pretty picture. Could a meltdown be on the way for Moderna stock?</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f6c071faeb9786d52d87adcab160eab7\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Lofty heights</h2>\n<p>There's no question that Moderna's valuation has reached lofty heights of late. The vaccine-maker's market cap is close to $130 billion, making Moderna <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the biggest biotech stocks on the market.</p>\n<p>Let's put that market cap in perspective. Moderna has one product on the market, compared to a multitude of products for <b>Pfizer</b>. Moderna's projected sales this year are only a fraction of what Pfizer will likely make. The company's pipeline looks tiny versus Pfizer's, and yet Moderna is now valued at more than half of Pfizer's market cap.</p>\n<p>Consider <b>Regeneron</b>&nbsp;and <b>Vertex</b>, two of the most successful biotechs around. Regeneron has multiple blockbuster drugs on the market, and Vertex enjoys a monopoly in treating the underlying cause of cystic fibrosis. Moderna is currently worth more than Regeneron and Vertex <i>combined</i>.</p>\n<h2>Considerable uncertainty</h2>\n<p>Moderna's valuation probably wouldn't be very concerning if the company could count on the revenue that it will make in 2021 and 2022 continuing over the long run. However, there's considerable uncertainty as to whether or not that will be the case.</p>\n<p>No one knows for sure how long Moderna's COVID-19 vaccine will provide protection against infection. The longer the duration of immunity, the fewer vaccine doses that the company will sell.</p>\n<p>Perhaps emerging coronavirus variants could force the need for booster doses. For now, though, Moderna's vaccine appears to be holding up relatively well against variants, especially in preventing severe cases of COVID-19.</p>\n<p>Remember, too, that Moderna's vaccine currently requires two doses. Even if booster shots are needed going forward, it's probable that only single shots will be used.</p>\n<p>This lower volume will negatively impact Moderna's future revenue unless the company doubles its price per dose. If Moderna took that option, though, it could set the stage for rivals to capture more market share.</p>\n<h2>A meltdown in the making?</h2>\n<p>A sky-high valuation plus serious questions about the future could add up to a meltdown in the making for many stocks. Will that happen with Moderna? Maybe.</p>\n<p>I've been bullish about Moderna for a long time. However, even I don't think it's worth more than half the market cap of Pfizer and more than Regeneron and Vertex combined.</p>\n<p>Still, though, I don't predict a meltdown for Moderna stock. Yes, I fully expect the biotech's shares will fall from current levels. However, my take is that there'll be more of a gradual decline instead of a crash.</p>\n<p>There's a real possibility that the current worries about the delta variant fade away. As those concerns decrease, so could Moderna's share price. But that's more likely to happen over a period of months instead of on a super-quick basis.</p>\n<p>Even if Moderna stock falls, as I think it eventually will, my view of the company's long-term prospects remains upbeat. I look for Moderna to crank out more successful messenger RNA (mRNA) vaccines and therapies over the next decade and beyond.</p>\n<p>The company won't be able to avoid Murphy's law forever. However, I anticipate that more will go right for Moderna over the long run than will go wrong.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is a Meltdown on the Way for Moderna Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs a Meltdown on the Way for Moderna Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 20:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/30/is-a-meltdown-on-the-way-for-moderna-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Move over, Murphy's law. Everything that could go right for Moderna (NASDAQ:MRNA) seems to be going right. The company was added to the S&P 500 index. Sales of its COVID-19 vaccine are booming, and ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/30/is-a-meltdown-on-the-way-for-moderna-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/07/30/is-a-meltdown-on-the-way-for-moderna-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155373781","content_text":"Move over, Murphy's law. Everything that could go right for Moderna (NASDAQ:MRNA) seems to be going right. The company was added to the S&P 500 index. Sales of its COVID-19 vaccine are booming, and its share price has more than tripled so far this year.\nHowever, all of this success could have some investors wondering just how long the momentum will last. And sometimes, when a good run ends, it isn't a pretty picture. Could a meltdown be on the way for Moderna stock?\nImage source: Getty Images.\nLofty heights\nThere's no question that Moderna's valuation has reached lofty heights of late. The vaccine-maker's market cap is close to $130 billion, making Moderna one of the biggest biotech stocks on the market.\nLet's put that market cap in perspective. Moderna has one product on the market, compared to a multitude of products for Pfizer. Moderna's projected sales this year are only a fraction of what Pfizer will likely make. The company's pipeline looks tiny versus Pfizer's, and yet Moderna is now valued at more than half of Pfizer's market cap.\nConsider Regeneron and Vertex, two of the most successful biotechs around. Regeneron has multiple blockbuster drugs on the market, and Vertex enjoys a monopoly in treating the underlying cause of cystic fibrosis. Moderna is currently worth more than Regeneron and Vertex combined.\nConsiderable uncertainty\nModerna's valuation probably wouldn't be very concerning if the company could count on the revenue that it will make in 2021 and 2022 continuing over the long run. However, there's considerable uncertainty as to whether or not that will be the case.\nNo one knows for sure how long Moderna's COVID-19 vaccine will provide protection against infection. The longer the duration of immunity, the fewer vaccine doses that the company will sell.\nPerhaps emerging coronavirus variants could force the need for booster doses. For now, though, Moderna's vaccine appears to be holding up relatively well against variants, especially in preventing severe cases of COVID-19.\nRemember, too, that Moderna's vaccine currently requires two doses. Even if booster shots are needed going forward, it's probable that only single shots will be used.\nThis lower volume will negatively impact Moderna's future revenue unless the company doubles its price per dose. If Moderna took that option, though, it could set the stage for rivals to capture more market share.\nA meltdown in the making?\nA sky-high valuation plus serious questions about the future could add up to a meltdown in the making for many stocks. Will that happen with Moderna? Maybe.\nI've been bullish about Moderna for a long time. However, even I don't think it's worth more than half the market cap of Pfizer and more than Regeneron and Vertex combined.\nStill, though, I don't predict a meltdown for Moderna stock. Yes, I fully expect the biotech's shares will fall from current levels. However, my take is that there'll be more of a gradual decline instead of a crash.\nThere's a real possibility that the current worries about the delta variant fade away. As those concerns decrease, so could Moderna's share price. But that's more likely to happen over a period of months instead of on a super-quick basis.\nEven if Moderna stock falls, as I think it eventually will, my view of the company's long-term prospects remains upbeat. I look for Moderna to crank out more successful messenger RNA (mRNA) vaccines and therapies over the next decade and beyond.\nThe company won't be able to avoid Murphy's law forever. However, I anticipate that more will go right for Moderna over the long run than will go wrong.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5380183,"gmtCreate":1627651494481,"gmtModify":1635164073136,"authorId":3581667328055955,"author":{"id":3581667328055955,"idStr":"3581667328055955","authorId":3581667328055955,"name":"Benedict_cyh","avatar":"https://static.tigerbbs.com/216a5cf2e56f81472309860a063b75a6","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":806856828,"type":1,"supId":0,"prevId":0,"content":"N","text":"N","html":"N"}],"langContent":"EN"},{"id":806851164,"gmtCreate":1627650826458,"gmtModify":1633757446050,"author":{"id":"4090562907967530","authorId":"4090562907967530","name":"Wolverine","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4090562907967530","authorIdStr":"4090562907967530"},"htmlText":"Yes please","listText":"Yes please","text":"Yes please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/806851164","repostId":2155373781,"repostType":4,"repost":{"id":"2155373781","pubTimestamp":1627647922,"share":"https://www.laohu8.com/m/news/2155373781?lang=&edition=full","pubTime":"2021-07-30 20:25","market":"us","language":"en","title":"Is a Meltdown on the Way for Moderna Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2155373781","media":"Motley Fool","summary":"There are certainly reasons to think the biotech stock is overpriced right now.","content":"<p>Move over, Murphy's law. Everything that could go right for&nbsp;<b>Moderna</b> (NASDAQ:MRNA) seems to be going right. The company was added to the <b>S&amp;P 500</b> index. Sales of its COVID-19 vaccine are booming, and its share price has more than tripled so far this year.</p>\n<p>However, all of this success could have some investors wondering just how long the momentum will last. And sometimes, when a good run ends, it isn't a pretty picture. Could a meltdown be on the way for Moderna stock?</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f6c071faeb9786d52d87adcab160eab7\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Lofty heights</h2>\n<p>There's no question that Moderna's valuation has reached lofty heights of late. The vaccine-maker's market cap is close to $130 billion, making Moderna <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the biggest biotech stocks on the market.</p>\n<p>Let's put that market cap in perspective. Moderna has one product on the market, compared to a multitude of products for <b>Pfizer</b>. Moderna's projected sales this year are only a fraction of what Pfizer will likely make. The company's pipeline looks tiny versus Pfizer's, and yet Moderna is now valued at more than half of Pfizer's market cap.</p>\n<p>Consider <b>Regeneron</b>&nbsp;and <b>Vertex</b>, two of the most successful biotechs around. Regeneron has multiple blockbuster drugs on the market, and Vertex enjoys a monopoly in treating the underlying cause of cystic fibrosis. Moderna is currently worth more than Regeneron and Vertex <i>combined</i>.</p>\n<h2>Considerable uncertainty</h2>\n<p>Moderna's valuation probably wouldn't be very concerning if the company could count on the revenue that it will make in 2021 and 2022 continuing over the long run. However, there's considerable uncertainty as to whether or not that will be the case.</p>\n<p>No one knows for sure how long Moderna's COVID-19 vaccine will provide protection against infection. The longer the duration of immunity, the fewer vaccine doses that the company will sell.</p>\n<p>Perhaps emerging coronavirus variants could force the need for booster doses. For now, though, Moderna's vaccine appears to be holding up relatively well against variants, especially in preventing severe cases of COVID-19.</p>\n<p>Remember, too, that Moderna's vaccine currently requires two doses. Even if booster shots are needed going forward, it's probable that only single shots will be used.</p>\n<p>This lower volume will negatively impact Moderna's future revenue unless the company doubles its price per dose. If Moderna took that option, though, it could set the stage for rivals to capture more market share.</p>\n<h2>A meltdown in the making?</h2>\n<p>A sky-high valuation plus serious questions about the future could add up to a meltdown in the making for many stocks. Will that happen with Moderna? Maybe.</p>\n<p>I've been bullish about Moderna for a long time. However, even I don't think it's worth more than half the market cap of Pfizer and more than Regeneron and Vertex combined.</p>\n<p>Still, though, I don't predict a meltdown for Moderna stock. Yes, I fully expect the biotech's shares will fall from current levels. However, my take is that there'll be more of a gradual decline instead of a crash.</p>\n<p>There's a real possibility that the current worries about the delta variant fade away. As those concerns decrease, so could Moderna's share price. But that's more likely to happen over a period of months instead of on a super-quick basis.</p>\n<p>Even if Moderna stock falls, as I think it eventually will, my view of the company's long-term prospects remains upbeat. I look for Moderna to crank out more successful messenger RNA (mRNA) vaccines and therapies over the next decade and beyond.</p>\n<p>The company won't be able to avoid Murphy's law forever. However, I anticipate that more will go right for Moderna over the long run than will go wrong.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is a Meltdown on the Way for Moderna Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs a Meltdown on the Way for Moderna Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 20:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/30/is-a-meltdown-on-the-way-for-moderna-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Move over, Murphy's law. Everything that could go right for Moderna (NASDAQ:MRNA) seems to be going right. The company was added to the S&P 500 index. Sales of its COVID-19 vaccine are booming, and ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/30/is-a-meltdown-on-the-way-for-moderna-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/07/30/is-a-meltdown-on-the-way-for-moderna-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155373781","content_text":"Move over, Murphy's law. Everything that could go right for Moderna (NASDAQ:MRNA) seems to be going right. The company was added to the S&P 500 index. Sales of its COVID-19 vaccine are booming, and its share price has more than tripled so far this year.\nHowever, all of this success could have some investors wondering just how long the momentum will last. And sometimes, when a good run ends, it isn't a pretty picture. Could a meltdown be on the way for Moderna stock?\nImage source: Getty Images.\nLofty heights\nThere's no question that Moderna's valuation has reached lofty heights of late. The vaccine-maker's market cap is close to $130 billion, making Moderna one of the biggest biotech stocks on the market.\nLet's put that market cap in perspective. Moderna has one product on the market, compared to a multitude of products for Pfizer. Moderna's projected sales this year are only a fraction of what Pfizer will likely make. The company's pipeline looks tiny versus Pfizer's, and yet Moderna is now valued at more than half of Pfizer's market cap.\nConsider Regeneron and Vertex, two of the most successful biotechs around. Regeneron has multiple blockbuster drugs on the market, and Vertex enjoys a monopoly in treating the underlying cause of cystic fibrosis. Moderna is currently worth more than Regeneron and Vertex combined.\nConsiderable uncertainty\nModerna's valuation probably wouldn't be very concerning if the company could count on the revenue that it will make in 2021 and 2022 continuing over the long run. However, there's considerable uncertainty as to whether or not that will be the case.\nNo one knows for sure how long Moderna's COVID-19 vaccine will provide protection against infection. The longer the duration of immunity, the fewer vaccine doses that the company will sell.\nPerhaps emerging coronavirus variants could force the need for booster doses. For now, though, Moderna's vaccine appears to be holding up relatively well against variants, especially in preventing severe cases of COVID-19.\nRemember, too, that Moderna's vaccine currently requires two doses. Even if booster shots are needed going forward, it's probable that only single shots will be used.\nThis lower volume will negatively impact Moderna's future revenue unless the company doubles its price per dose. If Moderna took that option, though, it could set the stage for rivals to capture more market share.\nA meltdown in the making?\nA sky-high valuation plus serious questions about the future could add up to a meltdown in the making for many stocks. Will that happen with Moderna? Maybe.\nI've been bullish about Moderna for a long time. However, even I don't think it's worth more than half the market cap of Pfizer and more than Regeneron and Vertex combined.\nStill, though, I don't predict a meltdown for Moderna stock. Yes, I fully expect the biotech's shares will fall from current levels. However, my take is that there'll be more of a gradual decline instead of a crash.\nThere's a real possibility that the current worries about the delta variant fade away. As those concerns decrease, so could Moderna's share price. But that's more likely to happen over a period of months instead of on a super-quick basis.\nEven if Moderna stock falls, as I think it eventually will, my view of the company's long-term prospects remains upbeat. I look for Moderna to crank out more successful messenger RNA (mRNA) vaccines and therapies over the next decade and beyond.\nThe company won't be able to avoid Murphy's law forever. However, I anticipate that more will go right for Moderna over the long run than will go wrong.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":806850699,"gmtCreate":1627650672811,"gmtModify":1631889873948,"author":{"id":"3574153250110529","authorId":"3574153250110529","name":"kjsin","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3574153250110529","authorIdStr":"3574153250110529"},"htmlText":"Murphy law!&nbsp;","listText":"Murphy law!&nbsp;","text":"Murphy law!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/806850699","repostId":2155373781,"repostType":4,"repost":{"id":"2155373781","pubTimestamp":1627647922,"share":"https://www.laohu8.com/m/news/2155373781?lang=&edition=full","pubTime":"2021-07-30 20:25","market":"us","language":"en","title":"Is a Meltdown on the Way for Moderna Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2155373781","media":"Motley Fool","summary":"There are certainly reasons to think the biotech stock is overpriced right now.","content":"<p>Move over, Murphy's law. Everything that could go right for&nbsp;<b>Moderna</b> (NASDAQ:MRNA) seems to be going right. The company was added to the <b>S&amp;P 500</b> index. Sales of its COVID-19 vaccine are booming, and its share price has more than tripled so far this year.</p>\n<p>However, all of this success could have some investors wondering just how long the momentum will last. And sometimes, when a good run ends, it isn't a pretty picture. Could a meltdown be on the way for Moderna stock?</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f6c071faeb9786d52d87adcab160eab7\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Lofty heights</h2>\n<p>There's no question that Moderna's valuation has reached lofty heights of late. The vaccine-maker's market cap is close to $130 billion, making Moderna <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the biggest biotech stocks on the market.</p>\n<p>Let's put that market cap in perspective. Moderna has one product on the market, compared to a multitude of products for <b>Pfizer</b>. Moderna's projected sales this year are only a fraction of what Pfizer will likely make. The company's pipeline looks tiny versus Pfizer's, and yet Moderna is now valued at more than half of Pfizer's market cap.</p>\n<p>Consider <b>Regeneron</b>&nbsp;and <b>Vertex</b>, two of the most successful biotechs around. Regeneron has multiple blockbuster drugs on the market, and Vertex enjoys a monopoly in treating the underlying cause of cystic fibrosis. Moderna is currently worth more than Regeneron and Vertex <i>combined</i>.</p>\n<h2>Considerable uncertainty</h2>\n<p>Moderna's valuation probably wouldn't be very concerning if the company could count on the revenue that it will make in 2021 and 2022 continuing over the long run. However, there's considerable uncertainty as to whether or not that will be the case.</p>\n<p>No one knows for sure how long Moderna's COVID-19 vaccine will provide protection against infection. The longer the duration of immunity, the fewer vaccine doses that the company will sell.</p>\n<p>Perhaps emerging coronavirus variants could force the need for booster doses. For now, though, Moderna's vaccine appears to be holding up relatively well against variants, especially in preventing severe cases of COVID-19.</p>\n<p>Remember, too, that Moderna's vaccine currently requires two doses. Even if booster shots are needed going forward, it's probable that only single shots will be used.</p>\n<p>This lower volume will negatively impact Moderna's future revenue unless the company doubles its price per dose. If Moderna took that option, though, it could set the stage for rivals to capture more market share.</p>\n<h2>A meltdown in the making?</h2>\n<p>A sky-high valuation plus serious questions about the future could add up to a meltdown in the making for many stocks. Will that happen with Moderna? Maybe.</p>\n<p>I've been bullish about Moderna for a long time. However, even I don't think it's worth more than half the market cap of Pfizer and more than Regeneron and Vertex combined.</p>\n<p>Still, though, I don't predict a meltdown for Moderna stock. Yes, I fully expect the biotech's shares will fall from current levels. However, my take is that there'll be more of a gradual decline instead of a crash.</p>\n<p>There's a real possibility that the current worries about the delta variant fade away. As those concerns decrease, so could Moderna's share price. But that's more likely to happen over a period of months instead of on a super-quick basis.</p>\n<p>Even if Moderna stock falls, as I think it eventually will, my view of the company's long-term prospects remains upbeat. I look for Moderna to crank out more successful messenger RNA (mRNA) vaccines and therapies over the next decade and beyond.</p>\n<p>The company won't be able to avoid Murphy's law forever. However, I anticipate that more will go right for Moderna over the long run than will go wrong.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is a Meltdown on the Way for Moderna Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs a Meltdown on the Way for Moderna Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 20:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/30/is-a-meltdown-on-the-way-for-moderna-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Move over, Murphy's law. Everything that could go right for Moderna (NASDAQ:MRNA) seems to be going right. The company was added to the S&P 500 index. Sales of its COVID-19 vaccine are booming, and ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/30/is-a-meltdown-on-the-way-for-moderna-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/07/30/is-a-meltdown-on-the-way-for-moderna-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155373781","content_text":"Move over, Murphy's law. Everything that could go right for Moderna (NASDAQ:MRNA) seems to be going right. The company was added to the S&P 500 index. Sales of its COVID-19 vaccine are booming, and its share price has more than tripled so far this year.\nHowever, all of this success could have some investors wondering just how long the momentum will last. And sometimes, when a good run ends, it isn't a pretty picture. Could a meltdown be on the way for Moderna stock?\nImage source: Getty Images.\nLofty heights\nThere's no question that Moderna's valuation has reached lofty heights of late. The vaccine-maker's market cap is close to $130 billion, making Moderna one of the biggest biotech stocks on the market.\nLet's put that market cap in perspective. Moderna has one product on the market, compared to a multitude of products for Pfizer. Moderna's projected sales this year are only a fraction of what Pfizer will likely make. The company's pipeline looks tiny versus Pfizer's, and yet Moderna is now valued at more than half of Pfizer's market cap.\nConsider Regeneron and Vertex, two of the most successful biotechs around. Regeneron has multiple blockbuster drugs on the market, and Vertex enjoys a monopoly in treating the underlying cause of cystic fibrosis. Moderna is currently worth more than Regeneron and Vertex combined.\nConsiderable uncertainty\nModerna's valuation probably wouldn't be very concerning if the company could count on the revenue that it will make in 2021 and 2022 continuing over the long run. However, there's considerable uncertainty as to whether or not that will be the case.\nNo one knows for sure how long Moderna's COVID-19 vaccine will provide protection against infection. The longer the duration of immunity, the fewer vaccine doses that the company will sell.\nPerhaps emerging coronavirus variants could force the need for booster doses. For now, though, Moderna's vaccine appears to be holding up relatively well against variants, especially in preventing severe cases of COVID-19.\nRemember, too, that Moderna's vaccine currently requires two doses. Even if booster shots are needed going forward, it's probable that only single shots will be used.\nThis lower volume will negatively impact Moderna's future revenue unless the company doubles its price per dose. If Moderna took that option, though, it could set the stage for rivals to capture more market share.\nA meltdown in the making?\nA sky-high valuation plus serious questions about the future could add up to a meltdown in the making for many stocks. Will that happen with Moderna? Maybe.\nI've been bullish about Moderna for a long time. However, even I don't think it's worth more than half the market cap of Pfizer and more than Regeneron and Vertex combined.\nStill, though, I don't predict a meltdown for Moderna stock. Yes, I fully expect the biotech's shares will fall from current levels. However, my take is that there'll be more of a gradual decline instead of a crash.\nThere's a real possibility that the current worries about the delta variant fade away. As those concerns decrease, so could Moderna's share price. But that's more likely to happen over a period of months instead of on a super-quick basis.\nEven if Moderna stock falls, as I think it eventually will, my view of the company's long-term prospects remains upbeat. I look for Moderna to crank out more successful messenger RNA (mRNA) vaccines and therapies over the next decade and beyond.\nThe company won't be able to avoid Murphy's law forever. However, I anticipate that more will go right for Moderna over the long run than will go wrong.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":806884174,"gmtCreate":1627649327398,"gmtModify":1633757463011,"author":{"id":"3587030474832187","authorId":"3587030474832187","name":"OoPiPi","avatar":"https://static.tigerbbs.com/9d08e95ca3ed272bd428558fc0aae8bc","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3587030474832187","authorIdStr":"3587030474832187"},"htmlText":"Comment and like please&nbsp;","listText":"Comment and like please&nbsp;","text":"Comment and like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/806884174","repostId":2155373781,"repostType":4,"repost":{"id":"2155373781","pubTimestamp":1627647922,"share":"https://www.laohu8.com/m/news/2155373781?lang=&edition=full","pubTime":"2021-07-30 20:25","market":"us","language":"en","title":"Is a Meltdown on the Way for Moderna Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2155373781","media":"Motley Fool","summary":"There are certainly reasons to think the biotech stock is overpriced right now.","content":"<p>Move over, Murphy's law. Everything that could go right for&nbsp;<b>Moderna</b> (NASDAQ:MRNA) seems to be going right. The company was added to the <b>S&amp;P 500</b> index. Sales of its COVID-19 vaccine are booming, and its share price has more than tripled so far this year.</p>\n<p>However, all of this success could have some investors wondering just how long the momentum will last. And sometimes, when a good run ends, it isn't a pretty picture. Could a meltdown be on the way for Moderna stock?</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f6c071faeb9786d52d87adcab160eab7\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Lofty heights</h2>\n<p>There's no question that Moderna's valuation has reached lofty heights of late. The vaccine-maker's market cap is close to $130 billion, making Moderna <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the biggest biotech stocks on the market.</p>\n<p>Let's put that market cap in perspective. Moderna has one product on the market, compared to a multitude of products for <b>Pfizer</b>. Moderna's projected sales this year are only a fraction of what Pfizer will likely make. The company's pipeline looks tiny versus Pfizer's, and yet Moderna is now valued at more than half of Pfizer's market cap.</p>\n<p>Consider <b>Regeneron</b>&nbsp;and <b>Vertex</b>, two of the most successful biotechs around. Regeneron has multiple blockbuster drugs on the market, and Vertex enjoys a monopoly in treating the underlying cause of cystic fibrosis. Moderna is currently worth more than Regeneron and Vertex <i>combined</i>.</p>\n<h2>Considerable uncertainty</h2>\n<p>Moderna's valuation probably wouldn't be very concerning if the company could count on the revenue that it will make in 2021 and 2022 continuing over the long run. However, there's considerable uncertainty as to whether or not that will be the case.</p>\n<p>No one knows for sure how long Moderna's COVID-19 vaccine will provide protection against infection. The longer the duration of immunity, the fewer vaccine doses that the company will sell.</p>\n<p>Perhaps emerging coronavirus variants could force the need for booster doses. For now, though, Moderna's vaccine appears to be holding up relatively well against variants, especially in preventing severe cases of COVID-19.</p>\n<p>Remember, too, that Moderna's vaccine currently requires two doses. Even if booster shots are needed going forward, it's probable that only single shots will be used.</p>\n<p>This lower volume will negatively impact Moderna's future revenue unless the company doubles its price per dose. If Moderna took that option, though, it could set the stage for rivals to capture more market share.</p>\n<h2>A meltdown in the making?</h2>\n<p>A sky-high valuation plus serious questions about the future could add up to a meltdown in the making for many stocks. Will that happen with Moderna? Maybe.</p>\n<p>I've been bullish about Moderna for a long time. However, even I don't think it's worth more than half the market cap of Pfizer and more than Regeneron and Vertex combined.</p>\n<p>Still, though, I don't predict a meltdown for Moderna stock. Yes, I fully expect the biotech's shares will fall from current levels. However, my take is that there'll be more of a gradual decline instead of a crash.</p>\n<p>There's a real possibility that the current worries about the delta variant fade away. As those concerns decrease, so could Moderna's share price. But that's more likely to happen over a period of months instead of on a super-quick basis.</p>\n<p>Even if Moderna stock falls, as I think it eventually will, my view of the company's long-term prospects remains upbeat. I look for Moderna to crank out more successful messenger RNA (mRNA) vaccines and therapies over the next decade and beyond.</p>\n<p>The company won't be able to avoid Murphy's law forever. However, I anticipate that more will go right for Moderna over the long run than will go wrong.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is a Meltdown on the Way for Moderna Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs a Meltdown on the Way for Moderna Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 20:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/30/is-a-meltdown-on-the-way-for-moderna-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Move over, Murphy's law. Everything that could go right for Moderna (NASDAQ:MRNA) seems to be going right. The company was added to the S&P 500 index. Sales of its COVID-19 vaccine are booming, and ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/30/is-a-meltdown-on-the-way-for-moderna-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/07/30/is-a-meltdown-on-the-way-for-moderna-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155373781","content_text":"Move over, Murphy's law. Everything that could go right for Moderna (NASDAQ:MRNA) seems to be going right. The company was added to the S&P 500 index. Sales of its COVID-19 vaccine are booming, and its share price has more than tripled so far this year.\nHowever, all of this success could have some investors wondering just how long the momentum will last. And sometimes, when a good run ends, it isn't a pretty picture. Could a meltdown be on the way for Moderna stock?\nImage source: Getty Images.\nLofty heights\nThere's no question that Moderna's valuation has reached lofty heights of late. The vaccine-maker's market cap is close to $130 billion, making Moderna one of the biggest biotech stocks on the market.\nLet's put that market cap in perspective. Moderna has one product on the market, compared to a multitude of products for Pfizer. Moderna's projected sales this year are only a fraction of what Pfizer will likely make. The company's pipeline looks tiny versus Pfizer's, and yet Moderna is now valued at more than half of Pfizer's market cap.\nConsider Regeneron and Vertex, two of the most successful biotechs around. Regeneron has multiple blockbuster drugs on the market, and Vertex enjoys a monopoly in treating the underlying cause of cystic fibrosis. Moderna is currently worth more than Regeneron and Vertex combined.\nConsiderable uncertainty\nModerna's valuation probably wouldn't be very concerning if the company could count on the revenue that it will make in 2021 and 2022 continuing over the long run. However, there's considerable uncertainty as to whether or not that will be the case.\nNo one knows for sure how long Moderna's COVID-19 vaccine will provide protection against infection. The longer the duration of immunity, the fewer vaccine doses that the company will sell.\nPerhaps emerging coronavirus variants could force the need for booster doses. For now, though, Moderna's vaccine appears to be holding up relatively well against variants, especially in preventing severe cases of COVID-19.\nRemember, too, that Moderna's vaccine currently requires two doses. Even if booster shots are needed going forward, it's probable that only single shots will be used.\nThis lower volume will negatively impact Moderna's future revenue unless the company doubles its price per dose. If Moderna took that option, though, it could set the stage for rivals to capture more market share.\nA meltdown in the making?\nA sky-high valuation plus serious questions about the future could add up to a meltdown in the making for many stocks. Will that happen with Moderna? Maybe.\nI've been bullish about Moderna for a long time. However, even I don't think it's worth more than half the market cap of Pfizer and more than Regeneron and Vertex combined.\nStill, though, I don't predict a meltdown for Moderna stock. Yes, I fully expect the biotech's shares will fall from current levels. However, my take is that there'll be more of a gradual decline instead of a crash.\nThere's a real possibility that the current worries about the delta variant fade away. As those concerns decrease, so could Moderna's share price. But that's more likely to happen over a period of months instead of on a super-quick basis.\nEven if Moderna stock falls, as I think it eventually will, my view of the company's long-term prospects remains upbeat. I look for Moderna to crank out more successful messenger RNA (mRNA) vaccines and therapies over the next decade and beyond.\nThe company won't be able to avoid Murphy's law forever. However, I anticipate that more will go right for Moderna over the long run than will go wrong.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5379936,"gmtCreate":1627649820515,"gmtModify":1635164090903,"authorId":3584307768549747,"author":{"id":3584307768549747,"idStr":"3584307768549747","authorId":3584307768549747,"name":"7cs","avatar":"https://static.tigerbbs.com/c280462a813e6bcb1d631a200079cef5","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":806884174,"type":1,"supId":0,"prevId":0,"content":"okay","text":"okay","html":"okay"}],"langContent":"EN"},{"id":806884037,"gmtCreate":1627649314729,"gmtModify":1633757463253,"author":{"id":"3587030474832187","authorId":"3587030474832187","name":"OoPiPi","avatar":"https://static.tigerbbs.com/9d08e95ca3ed272bd428558fc0aae8bc","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3587030474832187","authorIdStr":"3587030474832187"},"htmlText":"High tech vaccine utilising mRNA technology !&nbsp;","listText":"High tech vaccine utilising mRNA technology !&nbsp;","text":"High tech vaccine utilising mRNA technology !","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/806884037","repostId":2155373781,"repostType":4,"repost":{"id":"2155373781","pubTimestamp":1627647922,"share":"https://www.laohu8.com/m/news/2155373781?lang=&edition=full","pubTime":"2021-07-30 20:25","market":"us","language":"en","title":"Is a Meltdown on the Way for Moderna Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2155373781","media":"Motley Fool","summary":"There are certainly reasons to think the biotech stock is overpriced right now.","content":"<p>Move over, Murphy's law. Everything that could go right for&nbsp;<b>Moderna</b> (NASDAQ:MRNA) seems to be going right. The company was added to the <b>S&amp;P 500</b> index. Sales of its COVID-19 vaccine are booming, and its share price has more than tripled so far this year.</p>\n<p>However, all of this success could have some investors wondering just how long the momentum will last. And sometimes, when a good run ends, it isn't a pretty picture. Could a meltdown be on the way for Moderna stock?</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f6c071faeb9786d52d87adcab160eab7\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Lofty heights</h2>\n<p>There's no question that Moderna's valuation has reached lofty heights of late. The vaccine-maker's market cap is close to $130 billion, making Moderna <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the biggest biotech stocks on the market.</p>\n<p>Let's put that market cap in perspective. Moderna has one product on the market, compared to a multitude of products for <b>Pfizer</b>. Moderna's projected sales this year are only a fraction of what Pfizer will likely make. The company's pipeline looks tiny versus Pfizer's, and yet Moderna is now valued at more than half of Pfizer's market cap.</p>\n<p>Consider <b>Regeneron</b>&nbsp;and <b>Vertex</b>, two of the most successful biotechs around. Regeneron has multiple blockbuster drugs on the market, and Vertex enjoys a monopoly in treating the underlying cause of cystic fibrosis. Moderna is currently worth more than Regeneron and Vertex <i>combined</i>.</p>\n<h2>Considerable uncertainty</h2>\n<p>Moderna's valuation probably wouldn't be very concerning if the company could count on the revenue that it will make in 2021 and 2022 continuing over the long run. However, there's considerable uncertainty as to whether or not that will be the case.</p>\n<p>No one knows for sure how long Moderna's COVID-19 vaccine will provide protection against infection. The longer the duration of immunity, the fewer vaccine doses that the company will sell.</p>\n<p>Perhaps emerging coronavirus variants could force the need for booster doses. For now, though, Moderna's vaccine appears to be holding up relatively well against variants, especially in preventing severe cases of COVID-19.</p>\n<p>Remember, too, that Moderna's vaccine currently requires two doses. Even if booster shots are needed going forward, it's probable that only single shots will be used.</p>\n<p>This lower volume will negatively impact Moderna's future revenue unless the company doubles its price per dose. If Moderna took that option, though, it could set the stage for rivals to capture more market share.</p>\n<h2>A meltdown in the making?</h2>\n<p>A sky-high valuation plus serious questions about the future could add up to a meltdown in the making for many stocks. Will that happen with Moderna? Maybe.</p>\n<p>I've been bullish about Moderna for a long time. However, even I don't think it's worth more than half the market cap of Pfizer and more than Regeneron and Vertex combined.</p>\n<p>Still, though, I don't predict a meltdown for Moderna stock. Yes, I fully expect the biotech's shares will fall from current levels. However, my take is that there'll be more of a gradual decline instead of a crash.</p>\n<p>There's a real possibility that the current worries about the delta variant fade away. As those concerns decrease, so could Moderna's share price. But that's more likely to happen over a period of months instead of on a super-quick basis.</p>\n<p>Even if Moderna stock falls, as I think it eventually will, my view of the company's long-term prospects remains upbeat. I look for Moderna to crank out more successful messenger RNA (mRNA) vaccines and therapies over the next decade and beyond.</p>\n<p>The company won't be able to avoid Murphy's law forever. However, I anticipate that more will go right for Moderna over the long run than will go wrong.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is a Meltdown on the Way for Moderna Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs a Meltdown on the Way for Moderna Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 20:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/30/is-a-meltdown-on-the-way-for-moderna-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Move over, Murphy's law. Everything that could go right for Moderna (NASDAQ:MRNA) seems to be going right. The company was added to the S&P 500 index. Sales of its COVID-19 vaccine are booming, and ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/30/is-a-meltdown-on-the-way-for-moderna-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/07/30/is-a-meltdown-on-the-way-for-moderna-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155373781","content_text":"Move over, Murphy's law. Everything that could go right for Moderna (NASDAQ:MRNA) seems to be going right. The company was added to the S&P 500 index. Sales of its COVID-19 vaccine are booming, and its share price has more than tripled so far this year.\nHowever, all of this success could have some investors wondering just how long the momentum will last. And sometimes, when a good run ends, it isn't a pretty picture. Could a meltdown be on the way for Moderna stock?\nImage source: Getty Images.\nLofty heights\nThere's no question that Moderna's valuation has reached lofty heights of late. The vaccine-maker's market cap is close to $130 billion, making Moderna one of the biggest biotech stocks on the market.\nLet's put that market cap in perspective. Moderna has one product on the market, compared to a multitude of products for Pfizer. Moderna's projected sales this year are only a fraction of what Pfizer will likely make. The company's pipeline looks tiny versus Pfizer's, and yet Moderna is now valued at more than half of Pfizer's market cap.\nConsider Regeneron and Vertex, two of the most successful biotechs around. Regeneron has multiple blockbuster drugs on the market, and Vertex enjoys a monopoly in treating the underlying cause of cystic fibrosis. Moderna is currently worth more than Regeneron and Vertex combined.\nConsiderable uncertainty\nModerna's valuation probably wouldn't be very concerning if the company could count on the revenue that it will make in 2021 and 2022 continuing over the long run. However, there's considerable uncertainty as to whether or not that will be the case.\nNo one knows for sure how long Moderna's COVID-19 vaccine will provide protection against infection. The longer the duration of immunity, the fewer vaccine doses that the company will sell.\nPerhaps emerging coronavirus variants could force the need for booster doses. For now, though, Moderna's vaccine appears to be holding up relatively well against variants, especially in preventing severe cases of COVID-19.\nRemember, too, that Moderna's vaccine currently requires two doses. Even if booster shots are needed going forward, it's probable that only single shots will be used.\nThis lower volume will negatively impact Moderna's future revenue unless the company doubles its price per dose. If Moderna took that option, though, it could set the stage for rivals to capture more market share.\nA meltdown in the making?\nA sky-high valuation plus serious questions about the future could add up to a meltdown in the making for many stocks. Will that happen with Moderna? Maybe.\nI've been bullish about Moderna for a long time. However, even I don't think it's worth more than half the market cap of Pfizer and more than Regeneron and Vertex combined.\nStill, though, I don't predict a meltdown for Moderna stock. Yes, I fully expect the biotech's shares will fall from current levels. However, my take is that there'll be more of a gradual decline instead of a crash.\nThere's a real possibility that the current worries about the delta variant fade away. As those concerns decrease, so could Moderna's share price. But that's more likely to happen over a period of months instead of on a super-quick basis.\nEven if Moderna stock falls, as I think it eventually will, my view of the company's long-term prospects remains upbeat. I look for Moderna to crank out more successful messenger RNA (mRNA) vaccines and therapies over the next decade and beyond.\nThe company won't be able to avoid Murphy's law forever. However, I anticipate that more will go right for Moderna over the long run than will go wrong.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":806885178,"gmtCreate":1627649234094,"gmtModify":1633757463963,"author":{"id":"3580955744929134","authorId":"3580955744929134","name":"boonk","avatar":"https://static.tigerbbs.com/6e58310c6a80ddfbcb69e0989cda7858","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3580955744929134","authorIdStr":"3580955744929134"},"htmlText":"Yes please. Fall to 150&nbsp;","listText":"Yes please. Fall to 150&nbsp;","text":"Yes please. Fall to 150","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/806885178","repostId":2155373781,"repostType":4,"repost":{"id":"2155373781","pubTimestamp":1627647922,"share":"https://www.laohu8.com/m/news/2155373781?lang=&edition=full","pubTime":"2021-07-30 20:25","market":"us","language":"en","title":"Is a Meltdown on the Way for Moderna Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2155373781","media":"Motley Fool","summary":"There are certainly reasons to think the biotech stock is overpriced right now.","content":"<p>Move over, Murphy's law. Everything that could go right for&nbsp;<b>Moderna</b> (NASDAQ:MRNA) seems to be going right. The company was added to the <b>S&amp;P 500</b> index. Sales of its COVID-19 vaccine are booming, and its share price has more than tripled so far this year.</p>\n<p>However, all of this success could have some investors wondering just how long the momentum will last. And sometimes, when a good run ends, it isn't a pretty picture. Could a meltdown be on the way for Moderna stock?</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f6c071faeb9786d52d87adcab160eab7\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Lofty heights</h2>\n<p>There's no question that Moderna's valuation has reached lofty heights of late. The vaccine-maker's market cap is close to $130 billion, making Moderna <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the biggest biotech stocks on the market.</p>\n<p>Let's put that market cap in perspective. Moderna has one product on the market, compared to a multitude of products for <b>Pfizer</b>. Moderna's projected sales this year are only a fraction of what Pfizer will likely make. The company's pipeline looks tiny versus Pfizer's, and yet Moderna is now valued at more than half of Pfizer's market cap.</p>\n<p>Consider <b>Regeneron</b>&nbsp;and <b>Vertex</b>, two of the most successful biotechs around. Regeneron has multiple blockbuster drugs on the market, and Vertex enjoys a monopoly in treating the underlying cause of cystic fibrosis. Moderna is currently worth more than Regeneron and Vertex <i>combined</i>.</p>\n<h2>Considerable uncertainty</h2>\n<p>Moderna's valuation probably wouldn't be very concerning if the company could count on the revenue that it will make in 2021 and 2022 continuing over the long run. However, there's considerable uncertainty as to whether or not that will be the case.</p>\n<p>No one knows for sure how long Moderna's COVID-19 vaccine will provide protection against infection. The longer the duration of immunity, the fewer vaccine doses that the company will sell.</p>\n<p>Perhaps emerging coronavirus variants could force the need for booster doses. For now, though, Moderna's vaccine appears to be holding up relatively well against variants, especially in preventing severe cases of COVID-19.</p>\n<p>Remember, too, that Moderna's vaccine currently requires two doses. Even if booster shots are needed going forward, it's probable that only single shots will be used.</p>\n<p>This lower volume will negatively impact Moderna's future revenue unless the company doubles its price per dose. If Moderna took that option, though, it could set the stage for rivals to capture more market share.</p>\n<h2>A meltdown in the making?</h2>\n<p>A sky-high valuation plus serious questions about the future could add up to a meltdown in the making for many stocks. Will that happen with Moderna? Maybe.</p>\n<p>I've been bullish about Moderna for a long time. However, even I don't think it's worth more than half the market cap of Pfizer and more than Regeneron and Vertex combined.</p>\n<p>Still, though, I don't predict a meltdown for Moderna stock. Yes, I fully expect the biotech's shares will fall from current levels. However, my take is that there'll be more of a gradual decline instead of a crash.</p>\n<p>There's a real possibility that the current worries about the delta variant fade away. As those concerns decrease, so could Moderna's share price. But that's more likely to happen over a period of months instead of on a super-quick basis.</p>\n<p>Even if Moderna stock falls, as I think it eventually will, my view of the company's long-term prospects remains upbeat. I look for Moderna to crank out more successful messenger RNA (mRNA) vaccines and therapies over the next decade and beyond.</p>\n<p>The company won't be able to avoid Murphy's law forever. However, I anticipate that more will go right for Moderna over the long run than will go wrong.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is a Meltdown on the Way for Moderna Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs a Meltdown on the Way for Moderna Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 20:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/30/is-a-meltdown-on-the-way-for-moderna-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Move over, Murphy's law. Everything that could go right for Moderna (NASDAQ:MRNA) seems to be going right. The company was added to the S&P 500 index. Sales of its COVID-19 vaccine are booming, and ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/30/is-a-meltdown-on-the-way-for-moderna-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/07/30/is-a-meltdown-on-the-way-for-moderna-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155373781","content_text":"Move over, Murphy's law. Everything that could go right for Moderna (NASDAQ:MRNA) seems to be going right. The company was added to the S&P 500 index. Sales of its COVID-19 vaccine are booming, and its share price has more than tripled so far this year.\nHowever, all of this success could have some investors wondering just how long the momentum will last. And sometimes, when a good run ends, it isn't a pretty picture. Could a meltdown be on the way for Moderna stock?\nImage source: Getty Images.\nLofty heights\nThere's no question that Moderna's valuation has reached lofty heights of late. The vaccine-maker's market cap is close to $130 billion, making Moderna one of the biggest biotech stocks on the market.\nLet's put that market cap in perspective. Moderna has one product on the market, compared to a multitude of products for Pfizer. Moderna's projected sales this year are only a fraction of what Pfizer will likely make. The company's pipeline looks tiny versus Pfizer's, and yet Moderna is now valued at more than half of Pfizer's market cap.\nConsider Regeneron and Vertex, two of the most successful biotechs around. Regeneron has multiple blockbuster drugs on the market, and Vertex enjoys a monopoly in treating the underlying cause of cystic fibrosis. Moderna is currently worth more than Regeneron and Vertex combined.\nConsiderable uncertainty\nModerna's valuation probably wouldn't be very concerning if the company could count on the revenue that it will make in 2021 and 2022 continuing over the long run. However, there's considerable uncertainty as to whether or not that will be the case.\nNo one knows for sure how long Moderna's COVID-19 vaccine will provide protection against infection. The longer the duration of immunity, the fewer vaccine doses that the company will sell.\nPerhaps emerging coronavirus variants could force the need for booster doses. For now, though, Moderna's vaccine appears to be holding up relatively well against variants, especially in preventing severe cases of COVID-19.\nRemember, too, that Moderna's vaccine currently requires two doses. Even if booster shots are needed going forward, it's probable that only single shots will be used.\nThis lower volume will negatively impact Moderna's future revenue unless the company doubles its price per dose. If Moderna took that option, though, it could set the stage for rivals to capture more market share.\nA meltdown in the making?\nA sky-high valuation plus serious questions about the future could add up to a meltdown in the making for many stocks. Will that happen with Moderna? Maybe.\nI've been bullish about Moderna for a long time. However, even I don't think it's worth more than half the market cap of Pfizer and more than Regeneron and Vertex combined.\nStill, though, I don't predict a meltdown for Moderna stock. Yes, I fully expect the biotech's shares will fall from current levels. However, my take is that there'll be more of a gradual decline instead of a crash.\nThere's a real possibility that the current worries about the delta variant fade away. As those concerns decrease, so could Moderna's share price. But that's more likely to happen over a period of months instead of on a super-quick basis.\nEven if Moderna stock falls, as I think it eventually will, my view of the company's long-term prospects remains upbeat. I look for Moderna to crank out more successful messenger RNA (mRNA) vaccines and therapies over the next decade and beyond.\nThe company won't be able to avoid Murphy's law forever. However, I anticipate that more will go right for Moderna over the long run than will go wrong.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":806882928,"gmtCreate":1627649163864,"gmtModify":1631890434977,"author":{"id":"3582854998341736","authorId":"3582854998341736","name":"Staricelock","avatar":"https://static.tigerbbs.com/61ced7ebcf5103c30768f4f61038d8b5","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582854998341736","authorIdStr":"3582854998341736"},"htmlText":"Hmmm","listText":"Hmmm","text":"Hmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/806882928","repostId":2155373781,"repostType":4,"repost":{"id":"2155373781","pubTimestamp":1627647922,"share":"https://www.laohu8.com/m/news/2155373781?lang=&edition=full","pubTime":"2021-07-30 20:25","market":"us","language":"en","title":"Is a Meltdown on the Way for Moderna Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2155373781","media":"Motley Fool","summary":"There are certainly reasons to think the biotech stock is overpriced right now.","content":"<p>Move over, Murphy's law. Everything that could go right for&nbsp;<b>Moderna</b> (NASDAQ:MRNA) seems to be going right. The company was added to the <b>S&amp;P 500</b> index. Sales of its COVID-19 vaccine are booming, and its share price has more than tripled so far this year.</p>\n<p>However, all of this success could have some investors wondering just how long the momentum will last. And sometimes, when a good run ends, it isn't a pretty picture. Could a meltdown be on the way for Moderna stock?</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f6c071faeb9786d52d87adcab160eab7\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Lofty heights</h2>\n<p>There's no question that Moderna's valuation has reached lofty heights of late. The vaccine-maker's market cap is close to $130 billion, making Moderna <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the biggest biotech stocks on the market.</p>\n<p>Let's put that market cap in perspective. Moderna has one product on the market, compared to a multitude of products for <b>Pfizer</b>. Moderna's projected sales this year are only a fraction of what Pfizer will likely make. The company's pipeline looks tiny versus Pfizer's, and yet Moderna is now valued at more than half of Pfizer's market cap.</p>\n<p>Consider <b>Regeneron</b>&nbsp;and <b>Vertex</b>, two of the most successful biotechs around. Regeneron has multiple blockbuster drugs on the market, and Vertex enjoys a monopoly in treating the underlying cause of cystic fibrosis. Moderna is currently worth more than Regeneron and Vertex <i>combined</i>.</p>\n<h2>Considerable uncertainty</h2>\n<p>Moderna's valuation probably wouldn't be very concerning if the company could count on the revenue that it will make in 2021 and 2022 continuing over the long run. However, there's considerable uncertainty as to whether or not that will be the case.</p>\n<p>No one knows for sure how long Moderna's COVID-19 vaccine will provide protection against infection. The longer the duration of immunity, the fewer vaccine doses that the company will sell.</p>\n<p>Perhaps emerging coronavirus variants could force the need for booster doses. For now, though, Moderna's vaccine appears to be holding up relatively well against variants, especially in preventing severe cases of COVID-19.</p>\n<p>Remember, too, that Moderna's vaccine currently requires two doses. Even if booster shots are needed going forward, it's probable that only single shots will be used.</p>\n<p>This lower volume will negatively impact Moderna's future revenue unless the company doubles its price per dose. If Moderna took that option, though, it could set the stage for rivals to capture more market share.</p>\n<h2>A meltdown in the making?</h2>\n<p>A sky-high valuation plus serious questions about the future could add up to a meltdown in the making for many stocks. Will that happen with Moderna? Maybe.</p>\n<p>I've been bullish about Moderna for a long time. However, even I don't think it's worth more than half the market cap of Pfizer and more than Regeneron and Vertex combined.</p>\n<p>Still, though, I don't predict a meltdown for Moderna stock. Yes, I fully expect the biotech's shares will fall from current levels. However, my take is that there'll be more of a gradual decline instead of a crash.</p>\n<p>There's a real possibility that the current worries about the delta variant fade away. As those concerns decrease, so could Moderna's share price. But that's more likely to happen over a period of months instead of on a super-quick basis.</p>\n<p>Even if Moderna stock falls, as I think it eventually will, my view of the company's long-term prospects remains upbeat. I look for Moderna to crank out more successful messenger RNA (mRNA) vaccines and therapies over the next decade and beyond.</p>\n<p>The company won't be able to avoid Murphy's law forever. However, I anticipate that more will go right for Moderna over the long run than will go wrong.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is a Meltdown on the Way for Moderna Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs a Meltdown on the Way for Moderna Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 20:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/30/is-a-meltdown-on-the-way-for-moderna-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Move over, Murphy's law. Everything that could go right for Moderna (NASDAQ:MRNA) seems to be going right. The company was added to the S&P 500 index. Sales of its COVID-19 vaccine are booming, and ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/30/is-a-meltdown-on-the-way-for-moderna-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/07/30/is-a-meltdown-on-the-way-for-moderna-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155373781","content_text":"Move over, Murphy's law. Everything that could go right for Moderna (NASDAQ:MRNA) seems to be going right. The company was added to the S&P 500 index. Sales of its COVID-19 vaccine are booming, and its share price has more than tripled so far this year.\nHowever, all of this success could have some investors wondering just how long the momentum will last. And sometimes, when a good run ends, it isn't a pretty picture. Could a meltdown be on the way for Moderna stock?\nImage source: Getty Images.\nLofty heights\nThere's no question that Moderna's valuation has reached lofty heights of late. The vaccine-maker's market cap is close to $130 billion, making Moderna one of the biggest biotech stocks on the market.\nLet's put that market cap in perspective. Moderna has one product on the market, compared to a multitude of products for Pfizer. Moderna's projected sales this year are only a fraction of what Pfizer will likely make. The company's pipeline looks tiny versus Pfizer's, and yet Moderna is now valued at more than half of Pfizer's market cap.\nConsider Regeneron and Vertex, two of the most successful biotechs around. Regeneron has multiple blockbuster drugs on the market, and Vertex enjoys a monopoly in treating the underlying cause of cystic fibrosis. Moderna is currently worth more than Regeneron and Vertex combined.\nConsiderable uncertainty\nModerna's valuation probably wouldn't be very concerning if the company could count on the revenue that it will make in 2021 and 2022 continuing over the long run. However, there's considerable uncertainty as to whether or not that will be the case.\nNo one knows for sure how long Moderna's COVID-19 vaccine will provide protection against infection. The longer the duration of immunity, the fewer vaccine doses that the company will sell.\nPerhaps emerging coronavirus variants could force the need for booster doses. For now, though, Moderna's vaccine appears to be holding up relatively well against variants, especially in preventing severe cases of COVID-19.\nRemember, too, that Moderna's vaccine currently requires two doses. Even if booster shots are needed going forward, it's probable that only single shots will be used.\nThis lower volume will negatively impact Moderna's future revenue unless the company doubles its price per dose. If Moderna took that option, though, it could set the stage for rivals to capture more market share.\nA meltdown in the making?\nA sky-high valuation plus serious questions about the future could add up to a meltdown in the making for many stocks. Will that happen with Moderna? Maybe.\nI've been bullish about Moderna for a long time. However, even I don't think it's worth more than half the market cap of Pfizer and more than Regeneron and Vertex combined.\nStill, though, I don't predict a meltdown for Moderna stock. Yes, I fully expect the biotech's shares will fall from current levels. However, my take is that there'll be more of a gradual decline instead of a crash.\nThere's a real possibility that the current worries about the delta variant fade away. As those concerns decrease, so could Moderna's share price. But that's more likely to happen over a period of months instead of on a super-quick basis.\nEven if Moderna stock falls, as I think it eventually will, my view of the company's long-term prospects remains upbeat. I look for Moderna to crank out more successful messenger RNA (mRNA) vaccines and therapies over the next decade and beyond.\nThe company won't be able to avoid Murphy's law forever. However, I anticipate that more will go right for Moderna over the long run than will go wrong.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":806815754,"gmtCreate":1627648548678,"gmtModify":1633757469587,"author":{"id":"3586427066022075","authorId":"3586427066022075","name":"JeebeeTan","avatar":"https://static.tigerbbs.com/da4f50945d55300b216529b90399ccea","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3586427066022075","authorIdStr":"3586427066022075"},"htmlText":"👍🏻","listText":"👍🏻","text":"👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/806815754","repostId":2155373781,"repostType":4,"repost":{"id":"2155373781","pubTimestamp":1627647922,"share":"https://www.laohu8.com/m/news/2155373781?lang=&edition=full","pubTime":"2021-07-30 20:25","market":"us","language":"en","title":"Is a Meltdown on the Way for Moderna Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2155373781","media":"Motley Fool","summary":"There are certainly reasons to think the biotech stock is overpriced right now.","content":"<p>Move over, Murphy's law. Everything that could go right for&nbsp;<b>Moderna</b> (NASDAQ:MRNA) seems to be going right. The company was added to the <b>S&amp;P 500</b> index. Sales of its COVID-19 vaccine are booming, and its share price has more than tripled so far this year.</p>\n<p>However, all of this success could have some investors wondering just how long the momentum will last. And sometimes, when a good run ends, it isn't a pretty picture. Could a meltdown be on the way for Moderna stock?</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f6c071faeb9786d52d87adcab160eab7\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Lofty heights</h2>\n<p>There's no question that Moderna's valuation has reached lofty heights of late. The vaccine-maker's market cap is close to $130 billion, making Moderna <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the biggest biotech stocks on the market.</p>\n<p>Let's put that market cap in perspective. Moderna has one product on the market, compared to a multitude of products for <b>Pfizer</b>. Moderna's projected sales this year are only a fraction of what Pfizer will likely make. The company's pipeline looks tiny versus Pfizer's, and yet Moderna is now valued at more than half of Pfizer's market cap.</p>\n<p>Consider <b>Regeneron</b>&nbsp;and <b>Vertex</b>, two of the most successful biotechs around. Regeneron has multiple blockbuster drugs on the market, and Vertex enjoys a monopoly in treating the underlying cause of cystic fibrosis. Moderna is currently worth more than Regeneron and Vertex <i>combined</i>.</p>\n<h2>Considerable uncertainty</h2>\n<p>Moderna's valuation probably wouldn't be very concerning if the company could count on the revenue that it will make in 2021 and 2022 continuing over the long run. However, there's considerable uncertainty as to whether or not that will be the case.</p>\n<p>No one knows for sure how long Moderna's COVID-19 vaccine will provide protection against infection. The longer the duration of immunity, the fewer vaccine doses that the company will sell.</p>\n<p>Perhaps emerging coronavirus variants could force the need for booster doses. For now, though, Moderna's vaccine appears to be holding up relatively well against variants, especially in preventing severe cases of COVID-19.</p>\n<p>Remember, too, that Moderna's vaccine currently requires two doses. Even if booster shots are needed going forward, it's probable that only single shots will be used.</p>\n<p>This lower volume will negatively impact Moderna's future revenue unless the company doubles its price per dose. If Moderna took that option, though, it could set the stage for rivals to capture more market share.</p>\n<h2>A meltdown in the making?</h2>\n<p>A sky-high valuation plus serious questions about the future could add up to a meltdown in the making for many stocks. Will that happen with Moderna? Maybe.</p>\n<p>I've been bullish about Moderna for a long time. However, even I don't think it's worth more than half the market cap of Pfizer and more than Regeneron and Vertex combined.</p>\n<p>Still, though, I don't predict a meltdown for Moderna stock. Yes, I fully expect the biotech's shares will fall from current levels. However, my take is that there'll be more of a gradual decline instead of a crash.</p>\n<p>There's a real possibility that the current worries about the delta variant fade away. As those concerns decrease, so could Moderna's share price. But that's more likely to happen over a period of months instead of on a super-quick basis.</p>\n<p>Even if Moderna stock falls, as I think it eventually will, my view of the company's long-term prospects remains upbeat. I look for Moderna to crank out more successful messenger RNA (mRNA) vaccines and therapies over the next decade and beyond.</p>\n<p>The company won't be able to avoid Murphy's law forever. However, I anticipate that more will go right for Moderna over the long run than will go wrong.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is a Meltdown on the Way for Moderna Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs a Meltdown on the Way for Moderna Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 20:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/30/is-a-meltdown-on-the-way-for-moderna-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Move over, Murphy's law. Everything that could go right for Moderna (NASDAQ:MRNA) seems to be going right. The company was added to the S&P 500 index. Sales of its COVID-19 vaccine are booming, and ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/30/is-a-meltdown-on-the-way-for-moderna-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/07/30/is-a-meltdown-on-the-way-for-moderna-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155373781","content_text":"Move over, Murphy's law. Everything that could go right for Moderna (NASDAQ:MRNA) seems to be going right. The company was added to the S&P 500 index. Sales of its COVID-19 vaccine are booming, and its share price has more than tripled so far this year.\nHowever, all of this success could have some investors wondering just how long the momentum will last. And sometimes, when a good run ends, it isn't a pretty picture. Could a meltdown be on the way for Moderna stock?\nImage source: Getty Images.\nLofty heights\nThere's no question that Moderna's valuation has reached lofty heights of late. The vaccine-maker's market cap is close to $130 billion, making Moderna one of the biggest biotech stocks on the market.\nLet's put that market cap in perspective. Moderna has one product on the market, compared to a multitude of products for Pfizer. Moderna's projected sales this year are only a fraction of what Pfizer will likely make. The company's pipeline looks tiny versus Pfizer's, and yet Moderna is now valued at more than half of Pfizer's market cap.\nConsider Regeneron and Vertex, two of the most successful biotechs around. Regeneron has multiple blockbuster drugs on the market, and Vertex enjoys a monopoly in treating the underlying cause of cystic fibrosis. Moderna is currently worth more than Regeneron and Vertex combined.\nConsiderable uncertainty\nModerna's valuation probably wouldn't be very concerning if the company could count on the revenue that it will make in 2021 and 2022 continuing over the long run. However, there's considerable uncertainty as to whether or not that will be the case.\nNo one knows for sure how long Moderna's COVID-19 vaccine will provide protection against infection. The longer the duration of immunity, the fewer vaccine doses that the company will sell.\nPerhaps emerging coronavirus variants could force the need for booster doses. For now, though, Moderna's vaccine appears to be holding up relatively well against variants, especially in preventing severe cases of COVID-19.\nRemember, too, that Moderna's vaccine currently requires two doses. Even if booster shots are needed going forward, it's probable that only single shots will be used.\nThis lower volume will negatively impact Moderna's future revenue unless the company doubles its price per dose. If Moderna took that option, though, it could set the stage for rivals to capture more market share.\nA meltdown in the making?\nA sky-high valuation plus serious questions about the future could add up to a meltdown in the making for many stocks. Will that happen with Moderna? Maybe.\nI've been bullish about Moderna for a long time. However, even I don't think it's worth more than half the market cap of Pfizer and more than Regeneron and Vertex combined.\nStill, though, I don't predict a meltdown for Moderna stock. Yes, I fully expect the biotech's shares will fall from current levels. However, my take is that there'll be more of a gradual decline instead of a crash.\nThere's a real possibility that the current worries about the delta variant fade away. As those concerns decrease, so could Moderna's share price. But that's more likely to happen over a period of months instead of on a super-quick basis.\nEven if Moderna stock falls, as I think it eventually will, my view of the company's long-term prospects remains upbeat. I look for Moderna to crank out more successful messenger RNA (mRNA) vaccines and therapies over the next decade and beyond.\nThe company won't be able to avoid Murphy's law forever. However, I anticipate that more will go right for Moderna over the long run than will go wrong.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5379771,"gmtCreate":1627648655055,"gmtModify":1635164102886,"authorId":3582928437657110,"author":{"id":3582928437657110,"idStr":"3582928437657110","authorId":3582928437657110,"name":"CTigger","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":806815754,"type":1,"supId":0,"prevId":0,"content":"yep","text":"yep","html":"yep"},{"id":5379813,"gmtCreate":1627648932542,"gmtModify":1635164099868,"authorId":3578472165464903,"author":{"id":3578472165464903,"idStr":"3578472165464903","authorId":3578472165464903,"name":"Siewleerocks","avatar":"https://static.tigerbbs.com/f00504e0b6e3e8236e593d86c0ce08ed","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":806815754,"type":1,"supId":0,"prevId":0,"content":"Yes","text":"Yes","html":"Yes"}],"langContent":"EN"},{"id":806813417,"gmtCreate":1627648159339,"gmtModify":1631890987978,"author":{"id":"3579857427606142","authorId":"3579857427606142","name":"soybeans","avatar":"https://static.tigerbbs.com/c052dba69876e2fe6510af8195f464f3","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3579857427606142","authorIdStr":"3579857427606142"},"htmlText":"Chance to grab some Moderna if it&nbsp;ever happens.","listText":"Chance to grab some Moderna if it&nbsp;ever happens.","text":"Chance to grab some Moderna if it ever happens.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/806813417","repostId":2155373781,"repostType":4,"repost":{"id":"2155373781","pubTimestamp":1627647922,"share":"https://www.laohu8.com/m/news/2155373781?lang=&edition=full","pubTime":"2021-07-30 20:25","market":"us","language":"en","title":"Is a Meltdown on the Way for Moderna Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2155373781","media":"Motley Fool","summary":"There are certainly reasons to think the biotech stock is overpriced right now.","content":"<p>Move over, Murphy's law. Everything that could go right for&nbsp;<b>Moderna</b> (NASDAQ:MRNA) seems to be going right. The company was added to the <b>S&amp;P 500</b> index. Sales of its COVID-19 vaccine are booming, and its share price has more than tripled so far this year.</p>\n<p>However, all of this success could have some investors wondering just how long the momentum will last. And sometimes, when a good run ends, it isn't a pretty picture. Could a meltdown be on the way for Moderna stock?</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f6c071faeb9786d52d87adcab160eab7\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Lofty heights</h2>\n<p>There's no question that Moderna's valuation has reached lofty heights of late. The vaccine-maker's market cap is close to $130 billion, making Moderna <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the biggest biotech stocks on the market.</p>\n<p>Let's put that market cap in perspective. Moderna has one product on the market, compared to a multitude of products for <b>Pfizer</b>. Moderna's projected sales this year are only a fraction of what Pfizer will likely make. The company's pipeline looks tiny versus Pfizer's, and yet Moderna is now valued at more than half of Pfizer's market cap.</p>\n<p>Consider <b>Regeneron</b>&nbsp;and <b>Vertex</b>, two of the most successful biotechs around. Regeneron has multiple blockbuster drugs on the market, and Vertex enjoys a monopoly in treating the underlying cause of cystic fibrosis. Moderna is currently worth more than Regeneron and Vertex <i>combined</i>.</p>\n<h2>Considerable uncertainty</h2>\n<p>Moderna's valuation probably wouldn't be very concerning if the company could count on the revenue that it will make in 2021 and 2022 continuing over the long run. However, there's considerable uncertainty as to whether or not that will be the case.</p>\n<p>No one knows for sure how long Moderna's COVID-19 vaccine will provide protection against infection. The longer the duration of immunity, the fewer vaccine doses that the company will sell.</p>\n<p>Perhaps emerging coronavirus variants could force the need for booster doses. For now, though, Moderna's vaccine appears to be holding up relatively well against variants, especially in preventing severe cases of COVID-19.</p>\n<p>Remember, too, that Moderna's vaccine currently requires two doses. Even if booster shots are needed going forward, it's probable that only single shots will be used.</p>\n<p>This lower volume will negatively impact Moderna's future revenue unless the company doubles its price per dose. If Moderna took that option, though, it could set the stage for rivals to capture more market share.</p>\n<h2>A meltdown in the making?</h2>\n<p>A sky-high valuation plus serious questions about the future could add up to a meltdown in the making for many stocks. Will that happen with Moderna? Maybe.</p>\n<p>I've been bullish about Moderna for a long time. However, even I don't think it's worth more than half the market cap of Pfizer and more than Regeneron and Vertex combined.</p>\n<p>Still, though, I don't predict a meltdown for Moderna stock. Yes, I fully expect the biotech's shares will fall from current levels. However, my take is that there'll be more of a gradual decline instead of a crash.</p>\n<p>There's a real possibility that the current worries about the delta variant fade away. As those concerns decrease, so could Moderna's share price. But that's more likely to happen over a period of months instead of on a super-quick basis.</p>\n<p>Even if Moderna stock falls, as I think it eventually will, my view of the company's long-term prospects remains upbeat. I look for Moderna to crank out more successful messenger RNA (mRNA) vaccines and therapies over the next decade and beyond.</p>\n<p>The company won't be able to avoid Murphy's law forever. However, I anticipate that more will go right for Moderna over the long run than will go wrong.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is a Meltdown on the Way for Moderna Stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs a Meltdown on the Way for Moderna Stock?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-30 20:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/30/is-a-meltdown-on-the-way-for-moderna-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Move over, Murphy's law. Everything that could go right for Moderna (NASDAQ:MRNA) seems to be going right. The company was added to the S&P 500 index. Sales of its COVID-19 vaccine are booming, and ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/30/is-a-meltdown-on-the-way-for-moderna-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/07/30/is-a-meltdown-on-the-way-for-moderna-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2155373781","content_text":"Move over, Murphy's law. Everything that could go right for Moderna (NASDAQ:MRNA) seems to be going right. The company was added to the S&P 500 index. Sales of its COVID-19 vaccine are booming, and its share price has more than tripled so far this year.\nHowever, all of this success could have some investors wondering just how long the momentum will last. And sometimes, when a good run ends, it isn't a pretty picture. Could a meltdown be on the way for Moderna stock?\nImage source: Getty Images.\nLofty heights\nThere's no question that Moderna's valuation has reached lofty heights of late. The vaccine-maker's market cap is close to $130 billion, making Moderna one of the biggest biotech stocks on the market.\nLet's put that market cap in perspective. Moderna has one product on the market, compared to a multitude of products for Pfizer. Moderna's projected sales this year are only a fraction of what Pfizer will likely make. The company's pipeline looks tiny versus Pfizer's, and yet Moderna is now valued at more than half of Pfizer's market cap.\nConsider Regeneron and Vertex, two of the most successful biotechs around. Regeneron has multiple blockbuster drugs on the market, and Vertex enjoys a monopoly in treating the underlying cause of cystic fibrosis. Moderna is currently worth more than Regeneron and Vertex combined.\nConsiderable uncertainty\nModerna's valuation probably wouldn't be very concerning if the company could count on the revenue that it will make in 2021 and 2022 continuing over the long run. However, there's considerable uncertainty as to whether or not that will be the case.\nNo one knows for sure how long Moderna's COVID-19 vaccine will provide protection against infection. The longer the duration of immunity, the fewer vaccine doses that the company will sell.\nPerhaps emerging coronavirus variants could force the need for booster doses. For now, though, Moderna's vaccine appears to be holding up relatively well against variants, especially in preventing severe cases of COVID-19.\nRemember, too, that Moderna's vaccine currently requires two doses. Even if booster shots are needed going forward, it's probable that only single shots will be used.\nThis lower volume will negatively impact Moderna's future revenue unless the company doubles its price per dose. If Moderna took that option, though, it could set the stage for rivals to capture more market share.\nA meltdown in the making?\nA sky-high valuation plus serious questions about the future could add up to a meltdown in the making for many stocks. Will that happen with Moderna? Maybe.\nI've been bullish about Moderna for a long time. However, even I don't think it's worth more than half the market cap of Pfizer and more than Regeneron and Vertex combined.\nStill, though, I don't predict a meltdown for Moderna stock. Yes, I fully expect the biotech's shares will fall from current levels. However, my take is that there'll be more of a gradual decline instead of a crash.\nThere's a real possibility that the current worries about the delta variant fade away. As those concerns decrease, so could Moderna's share price. But that's more likely to happen over a period of months instead of on a super-quick basis.\nEven if Moderna stock falls, as I think it eventually will, my view of the company's long-term prospects remains upbeat. I look for Moderna to crank out more successful messenger RNA (mRNA) vaccines and therapies over the next decade and beyond.\nThe company won't be able to avoid Murphy's law forever. However, I anticipate that more will go right for Moderna over the long run than will go wrong.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5379843,"gmtCreate":1627649138048,"gmtModify":1631890988003,"authorId":3565954513972782,"author":{"id":3565954513972782,"idStr":"3565954513972782","authorId":3565954513972782,"name":"Coo24","avatar":"https://static.tigerbbs.com/8f9f40c3988dd98ed506a29a2b844507","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":806813417,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":5379793,"gmtCreate":1627648789926,"gmtModify":1631890987991,"authorId":3579775660085519,"author":{"id":3579775660085519,"idStr":"3579775660085519","authorId":3579775660085519,"name":"Matt_cjx","avatar":"https://static.tigerbbs.com/caca73862e27552f1ed9c206de3aedd3","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":806813417,"type":1,"supId":0,"prevId":0,"content":"Ha","text":"Ha","html":"Ha"},{"id":5379718,"gmtCreate":1627648260166,"gmtModify":1631890987974,"authorId":3562559237461627,"author":{"id":3562559237461627,"idStr":"3562559237461627","authorId":3562559237461627,"name":"AhSon","avatar":"https://static.tigerbbs.com/93b572e6d31fbbe91fbc1aeca083aee9","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":806813417,"type":1,"supId":0,"prevId":0,"content":"Is it","text":"Is it","html":"Is it"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":84,"commentSize":12,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}